Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine
NCT02426905
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
90
Enrollment
INDUSTRY
Sponsor class
Conditions
Wilson Disease
Interventions
DRUG:
trientine dihydrochloride
Sponsor
Univar BV